Cervical Cancer Screening and HPV: What Women Need to Know

Cervical cancer screening combines Pap smear cytology with human papillomavirus (HPV) testing to detect abnormal cervical cells before they progress to invasive disease. The United States Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) maintain evidence-based guidelines that define who should be screened, at what intervals, and with which tests. Understanding the relationship between HPV infection and cervical cancer risk is foundational to interpreting screening results and making informed decisions about follow-up care.

Definition and Scope

Cervical cancer arises almost exclusively from persistent infection with high-risk strains of human papillomavirus, a sexually transmitted infection (Centers for Disease Control and Prevention, HPV and Cancer). Of the more than 200 identified HPV types, the International Agency for Research on Cancer (IARC) classifies 12 strains as Group 1 carcinogens — confirmed causes of human cancer. Two strains, HPV 16 and HPV 18, account for approximately 70% of cervical cancers globally, according to the World Health Organization HPV and Cervical Cancer fact sheet.

Cervical cancer screening is the structured, population-level process of testing asymptomatic individuals to identify precancerous lesions — classified clinically as cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 — before invasive carcinoma develops. The USPSTF Cervical Cancer Screening Recommendation (2018) assigns this intervention a Grade A rating for women aged 21–65, indicating high certainty of substantial net benefit. This page sits alongside broader coverage of cervical health and Pap smears on this site, and connects to the regulatory context for women's health, which outlines how federal agencies govern preventive screening mandates.

Scope exclusions matter: the guidelines do not apply to individuals who have had a total hysterectomy with cervical removal for benign reasons, or to those over age 65 with adequate prior screening history and no high-risk factors.

How It Works

Cervical cancer screening operates through three distinct test modalities, each with different mechanisms and performance profiles.

1. Cytology (Pap Smear)
A clinician collects cells from the cervical transformation zone using a brush or spatula. A pathologist examines those cells under a microscope for morphological abnormalities. The Pap smear detects existing cellular changes but cannot identify HPV infection directly. Sensitivity for high-grade lesions is approximately 55–80% per individual test, according to the American Cancer Society Cervical Cancer Early Detection guide.

2. High-Risk HPV (hrHPV) Test
A molecular test — typically using polymerase chain reaction (PCR) or signal amplification — detects the DNA of high-risk HPV strains from the same cervical sample. The hrHPV test has higher sensitivity than cytology alone for detecting CIN 2+ lesions, with pooled sensitivity figures above 90% cited in systematic reviews published by the Agency for Healthcare Research and Quality (AHRQ).

3. Co-testing
Co-testing combines cytology and hrHPV testing simultaneously. The USPSTF identifies co-testing every 5 years as one of three acceptable strategies for women aged 30–65, alongside Pap-only every 3 years and hrHPV-only every 5 years (USPSTF, 2018).

The Affordable Care Act (ACA), under 42 U.S.C. § 300gg-13, requires non-grandfathered health plans to cover USPSTF Grade A and B preventive services — including cervical cancer screening — without cost sharing, which is further detailed in guidance from the Health Resources and Services Administration (HRSA).

Common Scenarios

Screening results generate one of five primary clinical scenarios, each carrying a defined management pathway per the American Society for Colposcopy and Cervical Pathology (ASCCP) 2019 Risk-Based Management Consensus Guidelines.

1. Normal cytology, hrHPV negative — Lowest risk category. Routine rescreening interval applies (3 or 5 years depending on test type).
2. Normal cytology, hrHPV positive — Intermediate risk. Reflex genotyping for HPV 16/18 or repeat co-testing in 1 year is recommended.
3. ASC-US (atypical squamous cells of undetermined significance), hrHPV negative — Risk is low; return to routine screening is appropriate.
4. ASC-US, hrHPV positive, or LSIL (low-grade squamous intraepithelial lesion) — Colposcopy referral is the standard pathway.
5. HSIL (high-grade squamous intraepithelial lesion) or ASC-H — Immediate colposcopy and biopsy are indicated regardless of hrHPV status.

The ASCCP framework uses a "risk-based" model, meaning management is determined by the estimated 5-year risk of CIN 3+ rather than by any single test result alone.

Decision Boundaries

Three major age-based boundaries define screening eligibility and strategy, as established by the USPSTF (2018) and the ACS 2020 Cervical Cancer Screening Guidelines:

• Under age 21: Screening is not recommended regardless of sexual history. HPV infections in adolescents typically clear spontaneously, and screening in this group produces net harm through unnecessary intervention.
• Ages 21–29: Cytology alone every 3 years. hrHPV testing is not recommended as a standalone or co-test primary screen because HPV prevalence is high and transient infection is common, leading to high false-positive rates.
• Ages 30–65: Three strategies are acceptable — Pap alone every 3 years, hrHPV alone every 5 years, or co-testing every 5 years. The ACS 2020 guidelines preferentially recommend primary hrHPV testing every 5 years for this age group.
• Over age 65: Screening may be discontinued if the individual has had 3 consecutive normal cytology results or 2 consecutive negative co-tests within the prior 10 years, with the most recent test within 5 years.

HPV vaccination does not eliminate the need for screening. The FDA-approved 9-valent vaccine (Gardasil 9) targets 9 HPV types, covering approximately 90% of cervical cancers, per the FDA Gardasil 9 prescribing information. However, vaccinated individuals remain susceptible to unvaccinated strains and may have acquired HPV prior to vaccination, making continued adherence to screening guidelines necessary for all eligible age groups.

A full overview of preventive care frameworks, including screening schedules across life stages, is available through the Women's Health Authority index.

References

• U.S. Preventive Services Task Force — Cervical Cancer Screening Recommendation (2018)
• American Cancer Society — Cervical Cancer Early Detection, Diagnosis, and Staging
• American Cancer Society — Cervical Cancer Screening Guidelines (2020)
• American Society for Colposcopy and Cervical Pathology (ASCCP) — 2019 Risk-Based Management Consensus Guidelines
• Centers for Disease Control and Prevention — HPV and Cancer
• World Health Organization — HPV and Cervical Cancer Fact Sheet
• FDA — Gardasil 9 Vaccine Information
• Health Resources and Services Administration (HRSA) — Women's Preventive Services Guidelines
• Agency for Healthcare Research and Quality (AHRQ)
• International Agency for Research on Cancer (IARC) — Monographs on HPV

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)